Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1984 5
1985 3
1986 3
1987 1
1988 1
1989 1
1992 3
1993 4
1994 6
1995 3
1997 2
1998 3
1999 6
2000 6
2001 6
2002 5
2003 4
2004 5
2005 12
2006 9
2007 3
2008 4
2009 11
2010 5
2011 5
2012 3
2013 9
2014 4
2015 8
2016 15
2017 8
2018 12
2019 6
2020 9
2021 10
2022 8
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients.
Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchétché D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators. Popma JJ, et al. N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16. N Engl J Med. 2019. PMID: 30883053 Clinical Trial.
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Mercuri E, Deconinck N, Mazzone ES, Nascimento A, Oskoui M, Saito K, Vuillerot C, Baranello G, Boespflug-Tanguy O, Goemans N, Kirschner J, Kostera-Pruszczyk A, Servais L, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Staunton H, Yeung WY, Martin C, Fontoura P, Day JW; SUNFISH Study Group. Mercuri E, et al. Lancet Neurol. 2022 Jan;21(1):42-52. doi: 10.1016/S1474-4422(21)00367-7. Lancet Neurol. 2022. PMID: 34942136
Vitronectin.
Schvartz I, Seger D, Shaltiel S. Schvartz I, et al. Among authors: seger d. Int J Biochem Cell Biol. 1999 May;31(5):539-44. doi: 10.1016/s1357-2725(99)00005-9. Int J Biochem Cell Biol. 1999. PMID: 10399314 Review.
The myth.
Seger D. Seger D. Toxicol Rev. 2005;24(3):155-6; discussion 159-60. doi: 10.2165/00139709-200524030-00005. Toxicol Rev. 2005. PMID: 16390214 No abstract available.
Heavy air.
Seger DL. Seger DL. Acad Emerg Med. 2011 Feb;18(2):226. doi: 10.1111/j.1553-2712.2010.00999.x. Acad Emerg Med. 2011. PMID: 21314786 Free article. No abstract available.
Systemic loxoscelism.
Parekh KP, Seger D. Parekh KP, et al. Among authors: seger d. Clin Toxicol (Phila). 2009 May;47(5):430-1. doi: 10.1080/15563650802555515. Clin Toxicol (Phila). 2009. PMID: 19274501 No abstract available.
Flumazenil--treatment or toxin.
Seger DL. Seger DL. J Toxicol Clin Toxicol. 2004;42(2):209-16. doi: 10.1081/clt-120030946. J Toxicol Clin Toxicol. 2004. PMID: 15214628 Review.
Clonidine toxicity revisited.
Seger DL. Seger DL. J Toxicol Clin Toxicol. 2002;40(2):145-55. doi: 10.1081/clt-120004402. J Toxicol Clin Toxicol. 2002. PMID: 12126186 Review.
Parallax view.
Seger D. Seger D. Clin Toxicol (Phila). 2005;43(1):13-5. doi: 10.1081/clt-50097. Clin Toxicol (Phila). 2005. PMID: 15732441 No abstract available.
196 results